Evidence map›Paper›PMID 39210332›Full record

Observational studyJournal of translational medicine2024

Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study.

Qing Liu, Mengling Liu, Zhiguo Zou, Jinyi Lin, Ningping Zhang, Lin Zhao, Jiahua Zhou, Haojie Zhou, Xin Zhou, Xiaodong Jiao and 2 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Immune checkpoint inhibitor-related myocarditis, myositis, and myasthenia gravis overlap syndrome: a single-center case series and systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Life Factors and Melanoma: From the Macroscopic State to the Molecular Mechanism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  11. Article
  12. Managing Advanced Squamous Cell Carcinoma: A Guide for the Dermatology Clinician.The Journal of clinical and aesthetic dermatology · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qing Liu *Department of Medical Oncology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Mengling Liu *Department of Medical Oncology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Zhiguo Zou *Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
Jinyi LinDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Ningping ZhangDepartment of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Lin ZhaoDepartment of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Jiahua ZhouDepartment of Oncology, Shanghai Construction Group (SCG) Hospital, Shanghai, 200083, China.
Haojie ZhouDepartment of Oncology, Shanghai Xuhui Central Hospital, Shanghai, 200031, China.
Xin ZhouDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Xiaodong JiaoDepartment of Medical Oncology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Yiyi YuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. yu.yiyi@zs-hospital.sh.cn.
Tianshu LiuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. liu.tianshu@zs-hospital.sh.cn.

Funding

Chinese Society of Clinical Oncology Y-2019AZQN-1014Shanghai Municipal Human Resources Development Program for Outstanding Leaders in Medical Disciplines 21PJD039Zhongshan Hospital No. 2020ZHZS02Zhongshan Hospital No. 2020ZSLC39Zhongshan Hospital No. 2022ZSQN09Zhongshan Hospital No. 2023ZYYS-016
6 · The paper itself

Abstract

backgroundTreatment strategy against immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) frequently requires other immunosuppressive agents. Tofacitinib is a rapidly acting JAK-STAT inhibitor with proven efficacy in multiple autoimmune diseases. We aimed to evaluate the efficacy and safety of tofacitinib in the management of irAEs in cancer patients.

methodsCancer patients who received ICIs and were treated with tofacitinib for the management of irAEs at 6 institutions were retrospectively included in this study. Demographic and clinical characteristics were obtained from electronic medical records. Longitudinal assessment of cardiac troponin T (cTnT) with clinical assessment was utilized to evaluate the benefit of tofacitinib treatment in patients with ICI myocarditis. Overall survival (OS) was also assessed.

resultsFifty-three patients were included in this study. The median time from irAE onset to tofacitinib therapy was 17 (range, 2-186) days and the median duration of tofacitinib treatment was 52.5 (range, 3-277) days. Enrolled patients were subdivided into 3 groups based on clinical severity and steroid responsiveness including 11 life-threatening cases, 30 steroid-resistant cases, and 12 cases with steroid taper failure. Clinical remission rate in each group was 54.5%, 96.7%, and 100%, respectively (P < 0.01). Tofacitinib was well-tolerated with 4 patients (7.5%) developing infectious events. From the ICI initiation, the overall median OS was 16.1 (95% CI 7.8-26.9) months.

conclusionTofacitinib showed promising clinical efficacy in patients experiencing irAEs, particularly in patients who failed to respond to steroids or experienced relapse during steroid tapering. Moreover, and most importantly, tofacitinib exhibited a favorable safety profile in cancer patients developing irAEs in terms of both toxicity and anti-tumor activity. Future prospective studies are warranted.

Indexed as

ImmunotherapyNeoplasmsPiperidinesPyrimidinesAdultAgedAged, 80 and overFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedRetrospective StudiesTreatment OutcomeImmune Checkpoint InhibitorsPiperidinesPyrimidinestofacitinibImmune-related adverse eventsImmunotherapyMyocarditisTofacitinib

Identifiers

PMID39210332
PMCPMC11360683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.